Media stories about Proteon Therapeutics (NASDAQ:PRTO) have been trending positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Proteon Therapeutics earned a daily sentiment score of 0.31 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near term.
Shares of Proteon Therapeutics (NASDAQ:PRTO) remained flat at $1.30 during midday trading on Friday. 24,239 shares of the company’s stock traded hands. The stock’s market capitalization is $21.80 million. The company has a 50-day moving average of $1.36 and a 200-day moving average of $1.59. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. Equities research analysts expect that Proteon Therapeutics will post ($1.65) earnings per share for the current fiscal year.
PRTO has been the subject of several recent research reports. HC Wainwright set a $3.00 price target on Proteon Therapeutics and gave the stock a “hold” rating in a research report on Saturday, May 13th. Zacks Investment Research downgraded Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Maxim Group set a $6.00 price target on Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $8.14.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.